Stay updated on Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.

Latest updates to the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe site’s displayed revision label changes from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record presents details of the completed Phase 2 study of nivolumab alone or with ipilimumab for resectable hepatocellular carcinoma, including its design, participant criteria, measured outcomes, and study documents.SummaryDifference60%

- Check22 days agoChange DetectedThe site footer revision changes from v3.7.2 to v3.8.0 while the study page continues to show a 403 error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide notice announces NIH website updates and a transition in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check36 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab +/- Ipilimumab for Liver Cancer Clinical Trial page.